189 related articles for article (PubMed ID: 12171874)
21. Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
Houghton JA; Williams LG; Cheshire PJ; Wainer IW; Jadaud P; Houghton PJ
Cancer Res; 1990 Jul; 50(13):3940-6. PubMed ID: 2354443
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.
Seymour MT; Slevin ML; Kerr DJ; Cunningham D; James RD; Ledermann JA; Perren TJ; McAdam WA; Harper PG; Neoptolemos JP; Nicholson M; Duffy AM; Stephens RJ; Stenning SP; Taylor I
J Clin Oncol; 1996 Aug; 14(8):2280-8. PubMed ID: 8708718
[TBL] [Abstract][Full Text] [Related]
23. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
Makower D; Wadler S
Semin Oncol; 1999 Dec; 26(6):663-71. PubMed ID: 10606259
[TBL] [Abstract][Full Text] [Related]
24. Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.
Ciccolini J; Peillard L; Evrard A; Cuq P; Aubert C; Pelegrin A; Formento P; Milano G; Catalin J
Clin Cancer Res; 2000 Apr; 6(4):1529-35. PubMed ID: 10778986
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of 5-fluorouracil (5-FUra) in patients with metastatic colorectal cancer receiving 5-FUra bolus plus continuous infusion with high dose folinic acid (LV5FU2).
Joulia JM; Pinguet F; Ychou M; Duffour J; Topart D; Grosse PY; Astre C; Bressolle F
Anticancer Res; 1997; 17(4A):2727-30. PubMed ID: 9252705
[TBL] [Abstract][Full Text] [Related]
27. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
Nogué M; Salud A; Batiste-Alentorn E; Saigí E; Losa F; Cirera L; Méndez M; Campos JM; Galan A; Escudero P; Arcusa A; Manzano H; de Mendizábal EV; de Olaguer JP; Boleda M; Guasch I; Vicente P
Eur J Cancer; 2005 Oct; 41(15):2241-9. PubMed ID: 16214045
[TBL] [Abstract][Full Text] [Related]
28. Preliminary results of a phase II trial for the treatment of metastatic breast cancer with 5-fluorouracil and leucovorin.
Allegra CJ; Chabner BA; Sholar PW; Bagley C; Drake JC; Lippman ME
NCI Monogr; 1987; (5):199-202. PubMed ID: 3501543
[TBL] [Abstract][Full Text] [Related]
29. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
30. Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.
Ajani JA; Rios AA; Ende K; Abbruzzese JL; Edwards C; Faintuch JS; Saks S; Gutterman JU; Levin B
J Biol Response Mod; 1989 Apr; 8(2):140-6. PubMed ID: 2499663
[TBL] [Abstract][Full Text] [Related]
31. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
Poplin EA; Benedetti JK; Estes NC; Haller DG; Mayer RJ; Goldberg RM; Weiss GR; Rivkin SE; Macdonald JS
J Clin Oncol; 2005 Mar; 23(9):1819-25. PubMed ID: 15774775
[TBL] [Abstract][Full Text] [Related]
32. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
33. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.
Schiller JH; Pugh M; Kirkwood JM; Karp D; Larson M; Borden E
Clin Cancer Res; 1996 Jan; 2(1):29-36. PubMed ID: 9816086
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
36. [Low-dose leucovorin and interferon-alpha as modulators of 5-fluorouracil for adjuvant chemotherapy of colorectal cancer].
Pajkos G; Bodoky G; Pádi E; Izsó J; Szántó J
Orv Hetil; 1998 Jun; 139(26):1571-5. PubMed ID: 9676118
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
38. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
39. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
Thirion P; Piedbois P; Buyse M; O'Dwyer PJ; Cunningham D; Man A; Greco FA; Colucci G; Köhne CH; Di Constanzo F; Piga A; Palmeri S; Dufour P; Cassano A; Pajkos G; Pensel RA; Aykan NF; Marsh J; Seymour MT;
Br J Cancer; 2001 Mar; 84(5):611-20. PubMed ID: 11237380
[TBL] [Abstract][Full Text] [Related]
40. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
Guglielmi A; Aschele C; Mori A; Baldo C; Russo P; Debernardis D; Valenti M; Bruno S; Taverna M; Rosso R
Clin Cancer Res; 1995 Nov; 1(11):1337-44. PubMed ID: 9815929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
